1. Market Research
  2. > Healthcare
  3. > Medical Device
  4. > Cardiovascular Devices Market Trends
  5. > Peripheral Transluminal Angioplasty Drug Eluting Balloons (DEB) - Pipeline Review, 2015

Peripheral Transluminal Angioplasty Drug Eluting Balloons (DEB) - Pipeline Review, 2015

Summary

GlobalData's Medical Devices sector report, “Peripheral Transluminal Angioplasty Drug Eluting Balloons (DEB) - Pipeline Review, 2015" provides an overview of Peripheral Transluminal Angioplasty (PTA) Drug Eluting Balloons (DEB) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Peripheral Transluminal Angioplasty Drug Eluting Balloons (DEB) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Peripheral Transluminal Angioplasty Drug Eluting Balloons (DEB) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Peripheral Transluminal Angioplasty Drug Eluting Balloons (DEB) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Peripheral Transluminal Angioplasty Drug Eluting Balloons (DEB) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table Of Contents

Peripheral Transluminal Angioplasty Drug Eluting Balloons (DEB) - Pipeline Review, 2015
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 6
2 Introduction 7
2.1 Peripheral Transluminal Angioplasty Drug Eluting Balloons (DEB) Overview 7
3 Products under Development 8
3.1 PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 8
3.2 PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory 9
3.3 PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path 11
3.4 PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date 13
3.5 PTA Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials 14
4 PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products under Development by Companies 15
4.1 PTA Peripheral Drug Eluting Balloons (DEB) Companies - Pipeline Products by Stage of Development 15
4.2 PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 16
5 PTA Peripheral Drug Eluting Balloons (DEB) Companies and Product Overview 17
5.1 AnGes MG, Inc. Company Overview 17
5.1.1 AnGes MG, Inc. Pipeline Products and Ongoing Clinical Trials Overview 17
5.2 AngioCure, Inc. Company Overview 19
5.2.1 AngioCure, Inc. Pipeline Products and Ongoing Clinical Trials Overview 19
5.3 AVIDAL Vascular GmbH Company Overview 20
5.3.1 AVIDAL Vascular GmbH Pipeline Products and Ongoing Clinical Trials Overview 20
5.4 Bayer HealthCare AG Company Overview 21
5.4.1 Bayer HealthCare AG Pipeline Products and Ongoing Clinical Trials Overview 21
5.5 C. R. Bard, Inc. Company Overview 24
5.5.1 C. R. Bard, Inc. Pipeline Products and Ongoing Clinical Trials Overview 24
5.6 Contego Medical, LLC Company Overview 28
5.6.1 Contego Medical, LLC Pipeline Products and Ongoing Clinical Trials Overview 28
5.7 eucatech AG Company Overview 29
5.7.1 eucatech AG Pipeline Products and Ongoing Clinical Trials Overview 29
5.8 Eurocor GmbH Company Overview 30
5.8.1 Eurocor GmbH Pipeline Products and Ongoing Clinical Trials Overview 30
5.9 Genesis Technologies, Inc (Inactive) Company Overview 34
5.9.1 Genesis Technologies, Inc (Inactive) Pipeline Products and Ongoing Clinical Trials Overview 34
5.10 Lifetech Scientific (Shenzhen) Co., Ltd. Company Overview 35
5.10.1 Lifetech Scientific (Shenzhen) Co., Ltd. Pipeline Products and Ongoing Clinical Trials Overview 35
5.11 Micell Technologies, Inc. Company Overview 36
5.11.1 Micell Technologies, Inc. Pipeline Products and Ongoing Clinical Trials Overview 36
5.12 Minvasys Company Overview 38
5.12.1 Minvasys Pipeline Products and Ongoing Clinical Trials Overview 38
5.13 Neovasc Inc. Company Overview 40
5.13.1 Neovasc Inc. Pipeline Products and Ongoing Clinical Trials Overview 40
5.14 Nipro Corporation Company Overview 42
5.14.1 Nipro Corporation Pipeline Products and Ongoing Clinical Trials Overview 42
5.15 QT Vascular Ltd. Company Overview 44
5.15.1 QT Vascular Ltd. Pipeline Products and Ongoing Clinical Trials Overview 44
5.16 Rontis AG Company Overview 47
5.16.1 Rontis AG Pipeline Products and Ongoing Clinical Trials Overview 47
5.17 SiL Vascular Ltd Company Overview 48
5.17.1 SiL Vascular Ltd Pipeline Products and Ongoing Clinical Trials Overview 48
5.18 SurModics, Inc. Company Overview 49
5.18.1 SurModics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 49
5.19 Terumo Corporation Company Overview 51
5.19.1 Terumo Corporation Pipeline Products and Ongoing Clinical Trials Overview 51
5.20 The Spectranetics Corporation Company Overview 53
5.20.1 The Spectranetics Corporation Pipeline Products and Ongoing Clinical Trials Overview 53
5.21 Vascular Nanotransfer Technologies Company Overview 57
5.21.1 Vascular Nanotransfer Technologies Pipeline Products and Ongoing Clinical Trials Overview 57
6 PTA Peripheral Drug Eluting Balloons (DEB)- Recent Developments 59
7 Appendix 77
7.1 Methodology 77
7.2 About GlobalData 79
7.3 Contact Us 80
7.4 Disclaimer 80

1.1 List of Tables
Table 1: PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 8
Table 2: PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory 10
Table 3: PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path 12
Table 4: PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date 13
Table 5: PTA Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials 14
Table 6: PTA Peripheral Drug Eluting Balloons (DEB) Companies - Pipeline Products by Stage of Development 15
Table 7: PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 16
Table 8: AnGes MG, Inc. Pipeline Products and Ongoing Clinical Trials Overview 17
Table 9: Collategene Drug-Eluting Balloon Catheter - Product Status 17
Table 10: Collategene Drug-Eluting Balloon Catheter - Product Description 18
Table 11: NF-kB Decoy Oligo Coated PTA Balloon Catheter - Product Status 18
Table 12: NF-kB Decoy Oligo Coated PTA Balloon Catheter - Product Description 18
Table 13: AngioCure, Inc. Pipeline Products and Ongoing Clinical Trials Overview 19
Table 14: AngioCure TOP-C Smart Balloon Catheter - Product Status 19
Table 15: AngioCure TOP-C Smart Balloon Catheter - Product Description 19
Table 16: AVIDAL Vascular GmbH Pipeline Products and Ongoing Clinical Trials Overview 20
Table 17: WOMBAT - Peripheral Version - Product Status 20
Table 18: WOMBAT - Peripheral Version - Product Description 20
Table 19: Bayer HealthCare AG Pipeline Products and Ongoing Clinical Trials Overview 21
Table 20: Cotavance Paclitaxel Coated Balloon Angioplasty Catheter - Product Status 21
Table 21: Cotavance Paclitaxel Coated Balloon Angioplasty Catheter - Product Description 22
Table 22: Bayer HealthCare AG - Ongoing Clinical Trials Overview 22
Table 23: Cotavance Paclitaxel Coated Balloon Angioplasty Catheter - Cotavance Paclitaxel-Coated Balloon Versus Uncoated Balloon Angioplasty for Treatment of In-stent Restenosis in SFA and Popliteal Arteries COPA CABANA Study 23
Table 24: Cotavance Paclitaxel Coated Balloon Angioplasty Catheter - European study of POBA versus Cotavance - Paclitaxel Coated Balloon for Infrapopliteal Lesions in Critical Limb Ischemia 23
Table 25: Cotavance Paclitaxel Coated Balloon Angioplasty Catheter - IDE Study of POBA versus Cotavance-Paclitaxel Coated Balloon for Infrapopliteal Lesions in Critical Limb Ischemia 23
Table 26: C. R. Bard, Inc. Pipeline Products and Ongoing Clinical Trials Overview 24
Table 27: Lutonix 014 DCB Catheter - Product Status 24
Table 28: Lutonix 014 DCB Catheter - Product Description 25
Table 29: C. R. Bard, Inc. - Ongoing Clinical Trials Overview 25
Table 30: Lutonix 014 DCB Catheter - A Prospective, Global Multicenter, Single Arm Real-World Registry Investigating the Clinical Use and Safety of the LUTONIX Drug Coated PTA Dilatation Catheter 26
Table 31: Lutonix 014 DCB Catheter - A Prospective, Multi-center, Registry of the Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries (LEVANT 2 Safety Registry) 26
Table 32: Lutonix 014 DCB Catheter - A Prospective, Multi-center, Single Blind, Randomized, Controlled Japanese Population Trial Comparing MD02-LDCB Versus Standard Balloon Angioplasty For Treatment Of Femoropopliteal Arteries 26
Table 33: Lutonix 014 DCB Catheter - A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Lutonix Drug Coated Balloon Versus Standard Balloon Angioplasty for Treatment of Below-the-Knee (BTK) Arteries (Lutonix BTK Trial) 27
Table 34: Contego Medical, LLC Pipeline Products and Ongoing Clinical Trials Overview 28
Table 35: Tibial Artery Drug Eluting Balloon - Product Status 28
Table 36: Tibial Artery Drug Eluting Balloon - Product Description 28
Table 37: eucatech AG Pipeline Products and Ongoing Clinical Trials Overview 29
Table 38: Support - Product Status 29
Table 39: Support - Product Description 29
Table 40: Eurocor GmbH Pipeline Products and Ongoing Clinical Trials Overview 30
Table 41: FREEWAY 014 Peripheral Drug Eluting Balloon - Product Status 30
Table 42: FREEWAY 014 Peripheral Drug Eluting Balloon - Product Description 31
Table 43: FREEWAY 035 Peripheral Drug-Eluting Balloon - Product Status 31
Table 44: FREEWAY 035 Peripheral Drug-Eluting Balloon - Product Description 32
Table 45: Eurocor GmbH - Ongoing Clinical Trials Overview 32
Table 46: FREEWAY 014 Peripheral Drug Eluting Balloon - Drug Eluting Balloon in Peripheral Intervention for Below-the-knee Arteries with Freeway and Lutonix 33
Table 47: FREEWAY 035 Peripheral Drug-Eluting Balloon - Drug Eluting Balloon in Peripheral Intervention for Below-the-knee Arteries with Freeway and Lutonix 33
Table 48: Genesis Technologies, Inc (Inactive) Pipeline Products and Ongoing Clinical Trials Overview 34
Table 49: Genesis DESA Balloon - Product Status 34
Table 50: Genesis DESA Balloon - Product Description 34
Table 51: Lifetech Scientific (Shenzhen) Co., Ltd. Pipeline Products and Ongoing Clinical Trials Overview 35
Table 52: PTA Drug Eluting Balloon - Product Status 35
Table 53: PTA Drug Eluting Balloon - Product Description 35
Table 54: Micell Technologies, Inc. Pipeline Products and Ongoing Clinical Trials Overview 36
Table 55: Drug-Coated Balloon - Product Status 36
Table 56: Drug-Coated Balloon - Product Description 37
Table 57: Minvasys Pipeline Products and Ongoing Clinical Trials Overview 38
Table 58: Danubio PTA Paclitaxel Eluting Over The Wire Balloon Catheter - Product Status 38
Table 59: Danubio PTA Paclitaxel Eluting Over The Wire Balloon Catheter - Product Description 38
Table 60: Danubio PTA Paclitaxel Eluting Rapid eXchange Balloon Catheter - Product Status 39
Table 61: Danubio PTA Paclitaxel Eluting Rapid eXchange Balloon Catheter - Product Description 39
Table 62: Neovasc Inc. Pipeline Products and Ongoing Clinical Trials Overview 40
Table 63: PTA Balloon Catheter - Product Status 40
Table 64: PTA Balloon Catheter - Product Description 41
Table 65: Nipro Corporation Pipeline Products and Ongoing Clinical Trials Overview 42
Table 66: Peripheral Drug-Eluting Balloon - Product Status 42
Table 67: Peripheral Drug-Eluting Balloon - Product Description 43
Table 68: QT Vascular Ltd. Pipeline Products and Ongoing Clinical Trials Overview 44
Table 69: Chocolate Touch PTA Drug Coated Balloon - Product Status 44
Table 70: Chocolate Touch PTA Drug Coated Balloon - Product Description 44
Table 71: Silk PTA Balloon Catheter - Product Status 45
Table 72: Silk PTA Balloon Catheter - Product Description 45
Table 73: QT Vascular Ltd. - Ongoing Clinical Trials Overview 45
Table 74: Chocolate Touch PTA Drug Coated Balloon - Clinical Study Evaluating the Chocolate Touch PTCA Coronary Drug-coated Balloon 46
Table 75: Rontis AG Pipeline Products and Ongoing Clinical Trials Overview 47
Table 76: Drug Eluting Dilatation Catheter - Product Status 47
Table 77: Drug Eluting Dilatation Catheter - Product Description 47
Table 78: SiL Vascular Ltd Pipeline Products and Ongoing Clinical Trials Overview 48
Table 79: Peripheral Vascular Balloon - Product Status 48
Table 80: Peripheral Vascular Balloon - Product Description 48
Table 81: SurModics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 49
Table 82: SurVeil Drug Coated Balloon - Arterio Venous (AV) Fistulas - Product Status 49
Table 83: SurVeil Drug Coated Balloon - Arterio Venous (AV) Fistulas - Product Description 50
Table 84: SurVeil Drug Coated Balloon - Below The Knee (BTK) - Product Status 50
Table 85: SurVeil Drug Coated Balloon - Below The Knee (BTK) - Product Description 50
Table 86: Terumo Corporation Pipeline Products and Ongoing Clinical Trials Overview 51
Table 87: Drug Coated Balloon Catheter - Product Status 51
Table 88: Drug Coated Balloon Catheter - Product Description 52
Table 89: The Spectranetics Corporation Pipeline Products and Ongoing Clinical Trials Overview 53
Table 90: Stellarex Drug Coated Balloon - Below The Knee (BTK) - Product Status 53
Table 91: Stellarex Drug Coated Balloon - Below The Knee (BTK) - Product Description 54
Table 92: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Product Status 54
Table 93: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Product Description 55
Table 94: The Spectranetics Corporation - Ongoing Clinical Trials Overview 55
Table 95: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Global Study Of A Drug-coated Balloon to Treat Obstructive SFA And/Or Popliteal Lesions 56
Table 96: Stellarex Drug Coated Balloon - Superficial Femoral Artery - ILLUMENATE First-in-Human (FIH) Study on the Safety and Effectiveness of Covidien's Advanced Drug-coated Balloon (DCB) Technology 56
Table 97: Stellarex Drug Coated Balloon - Superficial Femoral Artery - Prospective, Single-arm, Multi-center, Pharmacokinetic Study to Evaluate Treatment of Obstructive Superficial Femoral Artery or Popliteal Lesions with a Novel Paclitaxel-coated Percutaneous Angioplasty Balloon 56
Table 98: Vascular Nanotransfer Technologies Pipeline Products and Ongoing Clinical Trials Overview 57
Table 99: Mitomycin-Based Drug Coated Balloon - Peripheral - Product Status 57
Table 100: Mitomycin-Based Drug Coated Balloon - Peripheral - Product Description 57
Table 101: Paclitaxel-Based Drug Coated Balloon - Peripheral - Product Status 58
Table 102: Paclitaxel-Based Drug Coated Balloon - Peripheral - Product Description 58
Table 103: Glossary 78

1.2 List of Figures
Figure 1: PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Stage of Development 8
Figure 2: PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Territory 9
Figure 3: PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Regulatory Path 11
Figure 4: PTA Peripheral Drug Eluting Balloons (DEB) - Pipeline Products by Estimated Approval Date 13
Figure 5: PTA Peripheral Drug Eluting Balloons (DEB) - Ongoing Clinical Trials 14

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Denmark Cardiovascular Devices Market Outlook to 2022 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others

Denmark Cardiovascular Devices Market Outlook to 2022 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others

  • $ 5995
  • Industry report
  • September 2016
  • by Global Data

Denmark Cardiovascular Devices Market Outlook to 2022 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others Summary ...

Greece Cardiovascular Devices Market Outlook to 2022 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others

Greece Cardiovascular Devices Market Outlook to 2022 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others

  • $ 5995
  • Industry report
  • September 2016
  • by Global Data

Greece Cardiovascular Devices Market Outlook to 2022 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others Summary GlobalData’s ...

Ireland Cardiovascular Devices Market Outlook to 2022 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others

Ireland Cardiovascular Devices Market Outlook to 2022 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others

  • $ 5995
  • Industry report
  • September 2016
  • by Global Data

Ireland Cardiovascular Devices Market Outlook to 2022 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others Summary ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.